Moleculin announces investigator-initiated Phase 1B/2 study of Annamycin for pancreatic cancer

Moleculin Biotech, Inc.

Phase 1B/2 single-arm study of Annamycin for third-line advanced pancreatic cancer; investigator-initiated by Atlantic Health.
Moleculin supplies Annamycin and maintains IND; Dr. Angela Alistar (Atlantic Health) is principal investigator.
Estimated additional cost to Moleculin ~$1M from 2026 to 2030 for drug supply and testing.
Preclinical data shows Annamycin targets topoisomerase II, correlated with poor survival in pancreatic cancer.
Annamycin (naxtarubicin) has Fast Track and Orphan Drug status for AML; Orphan Drug for STS lung mets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.